Telix Pharmaceuticals Limited (TLPPF)

Telix Pharmaceuticals Balance Sheet

Financials in millions AUD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	123.24	116.33	22.04	77.95	44.6
Cash & Cash Equivalents	123.24	116.33	22.04	77.95	44.6
Cash Growth	5.94%	427.88%	-71.73%	74.77%	73.05%
Receivables	71.88	39.35	19.42	12.4	12.07
Inventory	17.31	8.48	3.45	0.63	0.54
Other Current Assets	12.42	9.07	2.63	2.65	1.47
Total Current Assets	224.85	173.23	47.54	93.63	58.68
Property, Plant & Equipment	30.49	18.84	6.33	4.82	1.9
Long-Term Investments	12.85	0	0	-6.62	0
Goodwill	4.85	5.52	4.1	4.22	4.22
Intangible Assets	104.82	53.47	51.63	54.97	37.72
Other Long-Term Assets	24.37	4.3	0.21	6.8	0.08
Total Long-Term Assets	177.37	82.12	62.27	64.19	43.93
Total Assets	402.22	255.35	109.81	157.82	102.61
Accounts Payable	32.84	16.81	11.88	5.81	6.96
Deferred Revenue	11	63.17	19.32	7.09	0
Current Debt	1.56	0.64	0.63	0.77	0.49
Other Current Liabilities	112.02	4.94	6.14	6.29	3.17
Total Current Liabilities	157.41	85.56	37.98	19.96	10.63
Long-Term Debt	8.21	9.81	1.91	1.44	1.64
Other Long-Term Liabilities	85.61	79.99	67.77	57.41	20.26
Total Long-Term Liabilities	93.82	89.79	69.67	58.85	21.9
Total Liabilities	251.22	175.35	107.66	78.81	32.53
Total Debt	17.45	10.45	2.54	2.21	2.13
Debt Growth	67.00%	311.42%	15.04%	3.57%	23.23%
Common Stock	446.27	370.97	170.84	167.06	115.94
Retained Earnings	-263.67	-272.82	-173.47	-92.96	-48.07
Comprehensive Income	-33.69	-18.15	4.79	4.92	2.21
Shareholders' Equity	148.91	80.01	2.16	79.02	70.08
Total Liabilities and Equity	402.22	255.35	109.81	157.82	102.61
Net Cash / Debt	105.79	105.88	19.5	75.74	42.47
Net Cash / Debt Growth	-0.09%	443.05%	-74.26%	78.35%	76.64%
Net Cash Per Share	0.33	0.34	0.07	0.29	0.18
Working Capital	67.44	87.68	9.56	73.67	48.05
Book Value Per Share	0.47	0.26	0.01	0.31	0.30

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.